Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis

• Published in: Journal of gastroenterology and hepatology Vol. 30; no. 9; pp. 1338 - 1345
• Main Authors: Kim, Joon Sung, Park, Sung Min, Kim, Byung-Wook
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01.09.2015
• Subjects: Amoxicillin - administration & dosage; Anti-Bacterial Agents - administration & dosage; Clarithromycin - administration & dosage; concomitant therapy; Databases, Bibliographic; Drug Therapy, Combination; Gastritis - drug therapy; Gastritis - microbiology; Helicobacter Infections; Helicobacter pylori; Humans; meta-analysis; Metronidazole - administration & dosage; Proton Pump Inhibitors - administration & dosage; Rho Guanine Nucleotide Exchange Factors - metabolism; sequential therapy; Treatment Outcome; sequential therapy; meta-analysis; concomitant therapy; Helicobacter pylori
• ISSN: 0815-9319; 1440-1746
• DOI: 10.1111/jgh.12984

Background and Aim Eradication of Helicobacter pylori (H. pylori) infection with triple therapy (TT) has declined in many countries prompting the search for alternative regimens. Sequential therapy (ST) and concomitant therapy (CT) have been suggested as first‐line regimens in areas of high clarithromycin resistance. We performed a meta‐analysis to compare the eradication rates of CT with ST for H. pylori. Methods A comprehensive literature search for studies comparing the efficacy of CT with ST was performed. Dichotomous data were pooled to obtain the odds ratio (OR) of the eradication rate with 95% confidence intervals (CIs). The eradication rates were considered both on an intention‐to‐treat (ITT) and on a per‐protocol (PP) bases. Results A total of 7 studies provided data on 2412 adult patients. Pooled estimates of the studies revealed no significant differences between CT and ST. The pooled OR was 1.116 (95% CI: 0.795–1.567, P = 0.526) for ITT analysis and 1.153 (95% CI: 0.793–1.677, P = 0.455) for PP analysis. There was no difference in the rate of adverse events (OR: 1.229, 95% CI: 0.971–1.556, P = 0.086) and compliance (OR: 0.945, 95% CI: 0.722–1.237, P = 0.681) between the two regimens. Subgroup analysis was performed to compare CT of 10 days and 5 days with ST of 10 days. The pooled OR was 1.518 for CT of 10days and 0.636 for CT of 5 days. Conclusions CT regimens did not achieve higher eradication rates compared with the ST regimen. The adverse events and adherence to medications were not different between the two regimens.